Epstein Barr Virus (EBV) - Market Insight, Epidemiology and Market Forecast - 2032

DelveInsight's 'Epstein-Barr Virus - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Epstein-Barr Virus in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

The Epstein-Barr Virus market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted Epstein-Barr Virus market size from 2019 to 2032, segmented by the 7MM. The report also covers the current Epstein-Barr Virus treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

• The United States
• EU4 and the United Kingdom
• Japan

Study period: 2019-2032

Epstein-Barr Virus: Disease Understanding and Treatment Algorithm

Epstein-Barr Virus Overview

Epstein-Barr Virus (EBV) is a common virus that remains dormant in most people. EBV causes infectious mononucleosis (IM) and has been associated with certain cancers, including Burkitt lymphoma, immunoblastic lymphoma, nasopharyngeal cancer, and stomach (gastric) cancer.

The transmission of EBV occurs in several ways, such as deep kissing or food-sharing. Increased levels of viral DNA are found in salivary secretions after the initial infection. Children can be infected after eating food that an EBV-infected individual has already chewed. The transmission has occurred through stem cells, organ transplantation, and blood transfusion.

The clinical presentation of the EBV infection usually overlaps with other acute viral syndromes caused by other viruses, such as Cytomegalovirus (CMV) and hepatitis viruses, which can lead to similar symptoms. Diagnostic schemes of EBV differ according to the patient's immune condition because the importance and urgency of therapeutic intervention differ between immunocompromised and immunocompetent individuals; a wide range of assays was utilized in diagnosing EBS.

Therapeutic strategies include prophylaxis, preemptive therapy, and targeted therapy. Rituximab, reduction of immunosuppression, and EBV-specific cytotoxic T-cell therapy are recommended as first-line therapy, whilst unselected donor lymphocyte infusions or chemotherapy are options as second-line therapy; other methods, including antiviral drugs, are discouraged.

Epstein-Barr Virus Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Epstein-Barr Virus market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

Epstein-Barr Virus Epidemiology

The Epstein-Barr Virus epidemiology division provides insights into the historical and current patient pool and the forecasted trend for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of KOL. The report also provides the prevalent patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Epstein-Barr Virus epidemiology segmented as the Diagnosed Incident Cases of Epstein-Barr Virus IM, Incident Cases of Epstein-Barr Virus + Cancer, Incident cases of Epstein-Barr Virus+ PTLD. The report includes the total Epstein-Barr Virus cases in the 7MM covering the United States, EU4 and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Epstein-Barr Virus Epidemiology

The epidemiology segment also provides the Epstein-Barr Virus epidemiology data and findings across the United States, EU4 and the United Kingdom, and Japan.

The total number of Epstein-Barr Virus IM cases in the 7MM countries was more than 1,120,000 in 2021.

As per the estimates, the United States had the highest number of incident cases of Epstein-Barr Virus in 2021. Among EU4 and the UK, Germany had the highest number of Epstein-Barr Virus cases, with more than 146,000 cases, followed by France in 2021. On the other hand, Spain had the lowest number of Epstein-Barr Virus cases, with close to 79,000 cases in 2021.

Epstein-Barr Virus Drug Chapters

The drug chapter segment of the Epstein-Barr Virus report encloses a detailed analysis of Epstein-Barr Virus-marketed drugs and late-stage (Phase III, Phase II/III, and Phase II) pipeline drugs. It also helps understand the Epstein-Barr Virus clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Treatment generally supports mononucleosis; antipyretics and anti-inflammatory medications help treat fever, sore throat, and general fatigue in this illness. Hydration, rest, and good nutritional intake should also be encouraged. Corticosteroids are not generally recommended in the routine treatment of mononucleosis because of concerns with immunosuppression; however, in cases of airway obstruction, corticosteroids are indicated along with appropriate airway management.

Products detail in the report…

Epstein-Barr Virus Emerging Drugs

Drug developers are gradually shifting their attention toward Epstein-Barr Virus to meet the patient pool's current demands and counter the unmet needs of the therapeutic market.

Many molecules are in the pipeline to treat Epstein-Barr Virus-associated infection patients across many countries to cater to their needs. Some of the major late-stage products are likely to hit the market during our study period 2019-2032 include tabelecleucel (Atara Biotherapeutics), posoleucel (AlloVir), and Nanatinostat + valganciclovir (Viracta Therapeutics).

Tabelecleucel: Atara Biotherapeutics

Tabelecleucel (Atara Biotherapeutics) is an off-the-shelf, allogeneic T-cell immunotherapy based on Atara Biotherapeutics' allogeneic T-cell immunotherapy platform. The drug has received BTD in the US, EMA Priority Medicines (PRIME) in Europe, and ODD in the US and EU for treatment of EBV+ PTLD following allogeneic hematopoietic cell transplant (HCT). The drug is currently in the late clinical phases for potentially treating patients with rituximab-refractory EBV+ PTLD. The therapy has received a marketing authorization recommendation from EMA in the EU for EBVALLO (tabelecleucel) to treat adult and pediatric patients who experience a serious complication following solid organ transplantation (SOT) or HCT called EBV+ PTLD.

Posoleucel (ALVR105): Allovir

Posoleucel (ALVR105), being investigated by AlloVir, is a multivirus specific T-cell therapy (VST) targeting five devastating viral pathogens: BK virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), EBV, and human herpesvirus 6 (HHV-6), that can transform care for transplant recipients as well as individuals who are at high risk for opportunistic viral infections by reducing or preventing disease morbidity and dramatically improving patient outcomes. The drug has received the ODD, PRIME designation in the EU, and RMAT designation from the US for treating serious infections with BKV, CMV, HHV-6, EBV, and/or AdV in allogeneic HSCT recipients. The therapy is currently being investigated in Phase II and III trials and is expected to get launched in the US market by 2024.

Products detail in the report…

Epstein-Barr Virus Market Outlook

The Epstein-Barr Virus market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Epstein-Barr Virus market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Epstein-Barr Virus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and KOL view. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

As per DelveInsight, the Epstein-Barr Virus market in the 7MM is expected to change in 2019-2032.

Key Findings

This section includes a glimpse of the Epstein-Barr Virus market in the 7MM. The Epstein-Barr Virus market size in the seven major markets was approximately USD 3,100 million in 2021.

The United States: Market Outlook

This section provides the total Epstein-Barr Virus market size and the market size of Epstein-Barr Virus by therapies in the United States.

The United States accounts for the largest Epstein-Barr Virus market size than EU4 and the United Kingdom, and Japan.

EU4 and the UK: Market Outlook

This section provides the total Epstein-Barr Virus market size. It also provides Epstein-Barr Virus market size by therapies in Germany, France, Italy, Spain, and the United Kingdom.

Japan Market Outlook

This section provides the total Epstein-Barr Virus market size. It also provides the market size of Epstein-Barr Virus by therapies in Japan.

Epstein-Barr Virus Drugs Uptake

This section focuses on the uptake rate of potential drugs launched or expected to be launched in the market during 2019-2032. The analysis covers the Epstein-Barr Virus market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and making financial and regulatory decisions.

Epstein-Barr Virus Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II. It also analyses Epstein-Barr Virus's key players in developing targeted therapeutics.

Major players include Atara Biotherapeutics and Allovir, whose key products are expected to get launched in the US market by 2028.

Pipeline Development Activities

The report covers collaborations, acquisitions, mergers, licensing, and patent details for emerging Epstein-Barr Virus therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the Epstein-Barr Virus domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging treatment patterns or Epstein-Barr Virus market trends. This will support the clients in potential novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a competitive and market intelligence analysis of the Epstein-Barr Virus market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG matrix, market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers a descriptive overview of the Epstein-Barr Virus, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
• Comprehensive insight is provided into the Epstein-Barr Virus epidemiology and treatment in the 7MM.
• An all-inclusive account of the current and emerging therapies for Epstein-Barr Virus is provided, along with the assessment of new therapies that will impact the current treatment landscape.
• A detailed review of the Epstein-Barr Virus market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Epstein-Barr Virus market.

Report Highlights:

• Recently, the Epstein-Barr Virus market has been set to change due to the increase in investment and research funding for Epstein-Barr Virus treatment, and the survival rates of those with Epstein-Barr Virus have increased because of advancements in treatment, such as blood and bone marrow stem cell transplants; which would expand the market size to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Epstein-Barr Virus R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Epstein-Barr Virus. Launching emerging therapies will significantly impact the Epstein-Barr Virus market.
• For Epstein-Barr Virus, a better understanding of disease pathogenesis will also contribute to developing novel therapeutics.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the R&D activities.

Epstein-Barr Virus Report Insights

• Patient Population
• Therapeutic Approaches
• Epstein-Barr Virus Pipeline Analysis
• Epstein-Barr Virus Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Epstein-Barr Virus Report Key Strengths

• 11-year Forecast
• The 7MM Coverage
• Epstein-Barr Virus Epidemiology Segmentation
• Key Competitors
• Highly Analyzed Market
• Drugs Uptake

Epstein-Barr Virus Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights

• What was the market share percentage distribution, and how would it look by 2032?
• What would be the total market size and market size of Epstein-Barr Virus by therapies across the 7MM forecast period (2019-2032)?
• What are the key findings about the market across the 7MM, and which country will have the largest Epstein-Barr Virus market size during the forecast period (2019-2032)?
• At what CAGR is the Epstein-Barr Virus market expected to grow in the 7MM forecast period (2019-2032)?
• What would be the Epstein-Barr Virus market outlook across the 7MM forecast period (2019-2032)?
• What would be the Epstein-Barr Virus market growth until 2032 and the resultant market size by 2032?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Epstein-Barr Virus?
• What is the historical patient pool of Epstein-Barr Virus covering the US, EU4 and the UK, and Japan?
• What would be the forecasted patient pool of Epstein-Barr Virus covering the US, EU4 and the UK, and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population of Epstein-Barr Virus?
• Out of all the 7MM, which country would have the highest prevalence of Epstein-Barr Virus during the forecast period (2019-2032)?
• At what CAGR is the population expected to grow in the 7MM forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options to treat Epstein-Barr Virus?
• What are the current treatment guidelines for treating Epstein-Barr Virus in the US, Europe, and Japan?
• What are the Epstein-Barr Virus-marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies to treat Epstein-Barr Virus?
• How many therapies are developed by each company to treat Epstein-Barr Virus?
• How many emerging therapies are in the mid-stage and late stages of development to treat Epstein-Barr Virus?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to Epstein-Barr Virus therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies for Epstein-Barr Virus and its status?
• Which key designations have been granted for the emerging therapies for Epstein-Barr Virus?
• What are the global historical and forecasted Epstein-Barr Virus markets?

Reasons to Buy:

• The report will help develop business strategies by understanding trends shaping and driving the Epstein-Barr Virus market.
• To understand the future market competition in the Epstein-Barr Virus market and an insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Epstein-Barr Virus in the US, EU4 (Germany, Spain, Italy, France) and the UK, and Japan.
• Identifying upcoming solid players in the market will help devise strategies that will help get ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Epstein-Barr Virus market.
• To understand the future market competition in the Epstein-Barr Virus market.